SCHEMBL182806

SCHEMBL182806

COCCNc1ccc(Br)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 1/20 0.59
ATM Q13315 1/20 0.52
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 2/20 0.50
NPC1 O15118 5/20 0.48
RAB9A P51151 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
PKM P14618 3/20 0.48
GAA P10253 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
MAPK1 P28482 1/20 0.46
MAPT P10636 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
LMNA P02545 1/20 0.43
MKNK1 Q9BUB5 2/20 0.42
FYN P06241 2/20 0.42
FDPS P14324 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15458128 0.83 ATM (0.46) HCAR3ATMALDH1A1KDM4ENPC1
SCHEMBL827800 0.81 HCAR3 (0.60) HCAR3ALDH1A1KDM4ERAB9AMAPT
SCHEMBL12963036 0.80 HCAR3 (0.56) HCAR3ATMALDH1A1KDM4ENPC1
SCHEMBL24896377 0.79 HCAR3 (0.59) HCAR3ALDH1A1KDM4ENPC1RAB9A
SCHEMBL2791509 0.79 HCAR3 (0.59) HCAR3ALDH1A1KDM4EMKNK1FYN
SCHEMBL31588400 0.79 HCAR3 (0.59) HCAR3ALDH1A1KDM4EMKNK1FYN
SCHEMBL15828788 0.79 NPC1 (0.48) HCAR3ATMALDH1A1KDM4ENPC1
SCHEMBL26679803 0.79 ABL1 (0.46) HCAR3ALDH1A1KDM4EHPGDTSHR
SCHEMBL15205661 0.79 ATM (0.43) HCAR3ATMALDH1A1KDM4ENPC1
SCHEMBL14416656 0.78 HCAR3 (0.57) HCAR3ALDH1A1KDM4EMKNK1FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2025-11-06 US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 US disclosed
US-11071736-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION 2021-07-27 US disclosed
US-11034671-B2 Apoptosis signal-regulating kinase inhibitors and uses thereof SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2021-06-15 US disclosed
US-20200283404-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2020-09-10 US disclosed
US-10588909-B2 Modulators of HEC1 activity and methods therefor TAIVEX THERAPEUTICS CORPORATION (TW) 2020-03-17 US disclosed
EP-3227287-B1 HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE Bayer Pharma AG (DE) 2019-08-07 EP disclosed
US-10292970-B2 Heteroaryl-substituted imidazo[1,2-A]pyridines and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-05-21 US disclosed
WO-2019051265-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF FRONTHERA U.S. PHARMACEUTICALS LLC (US) 2019-03-14 WO disclosed
EP-2785714-B1 IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORP (TW) 2018-11-21 EP disclosed
US-20130190312-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORPORATION (TW) 2013-07-25 US disclosed
WO-2013082324-A1 IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR TAIVEX THERAPEUTICS CORPORATION (TW) 2013-06-06 WO disclosed
US-20130035326-A1 BIARYL COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-02-07 US disclosed
EP-2467137-A1 BIARYL COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2012-06-27 EP disclosed
CN-102470127-A Biaryl compounds and methods of use thereof AMBIT BIOSCIENCES CORP 2012-05-23 CN disclosed
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP disclosed
WO-2011022473-A1 BIARYL COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2011-02-24 WO disclosed
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors NOVARTIS AG 2009-10-15 US disclosed
EP-2049502-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2009-04-22 EP disclosed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200283404-A1 APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF DAPK1, ATF1, BAD HCAR3 3598/4885ATM 54/4885ALDH1A1 3022/4885
US-11034671-B2 Apoptosis signal-regulating kinase inhibitors and uses thereof DAPK1, ATF1, BAD HCAR3 3598/4885ATM 54/4885ALDH1A1 3022/4885
US-20130190312-A1 MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR WEE1, WEE2, NEK11 HCAR3 2598/4885ATM 3043/4885ALDH1A1 3121/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 HCAR3 721/4885ATM 1026/4885ALDH1A1 959/4885
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, STAT1, STAT5B HCAR3 1332/4885ATM 485/4885ALDH1A1 2050/4885
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors PDPK1, PI4KA, PIK3CA HCAR3 2588/4885ATM 733/4885ALDH1A1 1849/4885
US-10588909-B2 Modulators of HEC1 activity and methods therefor WEE1, WEE2, NEK11 HCAR3 2598/4885ATM 3043/4885ALDH1A1 3121/4885
US-11071736-B2 Modulators of HEC1 activity and methods therefor WEE1, WEE2, NEK11 HCAR3 2598/4885ATM 3043/4885ALDH1A1 3121/4885
US-20130035326-A1 BIARYL COMPOUNDS AND METHODS OF USE THEREOF FLT3, CSF3R, CSF1R HCAR3 1319/4885ATM 179/4885ALDH1A1 1695/4885
US-10292970-B2 Heteroaryl-substituted imidazo[1,2-A]pyridines and their use TNNI3, CYP11B2, PPIP5K2 HCAR3 805/4885ATM 2658/4885ALDH1A1 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.